Mitochondrial STAT3 contributes to transformation of barrett’s epithelial cells that express oncogenic ras in a p53-independent fashion

Chunhua Yu, Xiaofang Huo, Agoston T. Agoston, Xi Zhang, Arianne L. Theiss, Edaire Cheng, Qiuyang Zhang, Alexander Zaika, Thai H. Pham, David H. Wang, Peter E. Lobie, Robert D. Odze, Stuart J. Spechler, Rhonda F. Souza

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Metaplastic epithelial cells of Barrett’s esophagus transformed by the combination of p53-knockdown and oncogenic Ras expression are known to activate signal transducer and activator of transcription 3 (STAT3). When phosphorylated at tyrosine 705 (Tyr705), STAT3 functions as a nuclear transcription factor that can contribute to oncogenesis. STAT3 phosphorylated at serine 727 (Ser727) localizes in mitochondria, but little is known about mitochondrial STAT3’s contribution to carcinogenesis in Barrett’s esophagus, which is the focus of this study. We introduced a constitutively active variant of human STAT3 (STAT3CA) into the following: 1) non-neoplastic Barrett’s (BAR-T) cells; 2) BAR-T cells with p53 knockdown; and 3) BAR-T cells that express oncogenic H-RasG12V. STAT3CA transformed only the H-RasG12V-expressing BAR-T cells (evidenced by loss of contact inhibition, formation of colonies in soft agar, and generation of tumors in immunodeficient mice), and did so in a p53-independent fashion. The transformed cells had elevated levels of both mitochondrial (Ser727) and nuclear (Tyr705) phospho-STAT3. Introduction of a STAT3CA construct with a mutated tyrosine phosphorylation site into H-RasG12V-expressing Barrett’s cells resulted in high levels of mitochondrial phospho-STAT3 (Ser727) with little or no nuclear phospho-STAT3 (Tyr705), and the cells still formed tumors in immunodeficient mice. Thus tyrosine phosphorylation of STAT3 is not required for tumor formation in Ras-expressing Barrett’s cells. We conclude that mitochondrial STAT3 (Ser727) can contribute to oncogenesis in Barrett’s cells that express oncogenic Ras. These findings suggest that agents targeting STAT3 might be useful for chemoprevention in patients with Barrett’s esophagus.

Original languageEnglish (US)
Pages (from-to)G146-G161
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume309
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

STAT3 Transcription Factor
Epithelial Cells
Serine
Barrett Esophagus
Tyrosine
Carcinogenesis
Phosphorylation
Contact Inhibition
Neoplasms
Chemoprevention
Agar
Mitochondria
Transcription Factors

Keywords

  • Esophagus
  • Human
  • Nuclear
  • Tumorigenesis
  • Xenograft

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Cite this

Mitochondrial STAT3 contributes to transformation of barrett’s epithelial cells that express oncogenic ras in a p53-independent fashion. / Yu, Chunhua; Huo, Xiaofang; Agoston, Agoston T.; Zhang, Xi; Theiss, Arianne L.; Cheng, Edaire; Zhang, Qiuyang; Zaika, Alexander; Pham, Thai H.; Wang, David H.; Lobie, Peter E.; Odze, Robert D.; Spechler, Stuart J.; Souza, Rhonda F.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 309, No. 3, 01.01.2015, p. G146-G161.

Research output: Contribution to journalArticle

Yu, C, Huo, X, Agoston, AT, Zhang, X, Theiss, AL, Cheng, E, Zhang, Q, Zaika, A, Pham, TH, Wang, DH, Lobie, PE, Odze, RD, Spechler, SJ & Souza, RF 2015, 'Mitochondrial STAT3 contributes to transformation of barrett’s epithelial cells that express oncogenic ras in a p53-independent fashion', American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 309, no. 3, pp. G146-G161. https://doi.org/10.1152/ajpgi.00462.2014
Yu, Chunhua ; Huo, Xiaofang ; Agoston, Agoston T. ; Zhang, Xi ; Theiss, Arianne L. ; Cheng, Edaire ; Zhang, Qiuyang ; Zaika, Alexander ; Pham, Thai H. ; Wang, David H. ; Lobie, Peter E. ; Odze, Robert D. ; Spechler, Stuart J. ; Souza, Rhonda F. / Mitochondrial STAT3 contributes to transformation of barrett’s epithelial cells that express oncogenic ras in a p53-independent fashion. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2015 ; Vol. 309, No. 3. pp. G146-G161.
@article{6637a99f799e4d1f8c7f2840e7f00213,
title = "Mitochondrial STAT3 contributes to transformation of barrett’s epithelial cells that express oncogenic ras in a p53-independent fashion",
abstract = "Metaplastic epithelial cells of Barrett’s esophagus transformed by the combination of p53-knockdown and oncogenic Ras expression are known to activate signal transducer and activator of transcription 3 (STAT3). When phosphorylated at tyrosine 705 (Tyr705), STAT3 functions as a nuclear transcription factor that can contribute to oncogenesis. STAT3 phosphorylated at serine 727 (Ser727) localizes in mitochondria, but little is known about mitochondrial STAT3’s contribution to carcinogenesis in Barrett’s esophagus, which is the focus of this study. We introduced a constitutively active variant of human STAT3 (STAT3CA) into the following: 1) non-neoplastic Barrett’s (BAR-T) cells; 2) BAR-T cells with p53 knockdown; and 3) BAR-T cells that express oncogenic H-RasG12V. STAT3CA transformed only the H-RasG12V-expressing BAR-T cells (evidenced by loss of contact inhibition, formation of colonies in soft agar, and generation of tumors in immunodeficient mice), and did so in a p53-independent fashion. The transformed cells had elevated levels of both mitochondrial (Ser727) and nuclear (Tyr705) phospho-STAT3. Introduction of a STAT3CA construct with a mutated tyrosine phosphorylation site into H-RasG12V-expressing Barrett’s cells resulted in high levels of mitochondrial phospho-STAT3 (Ser727) with little or no nuclear phospho-STAT3 (Tyr705), and the cells still formed tumors in immunodeficient mice. Thus tyrosine phosphorylation of STAT3 is not required for tumor formation in Ras-expressing Barrett’s cells. We conclude that mitochondrial STAT3 (Ser727) can contribute to oncogenesis in Barrett’s cells that express oncogenic Ras. These findings suggest that agents targeting STAT3 might be useful for chemoprevention in patients with Barrett’s esophagus.",
keywords = "Esophagus, Human, Nuclear, Tumorigenesis, Xenograft",
author = "Chunhua Yu and Xiaofang Huo and Agoston, {Agoston T.} and Xi Zhang and Theiss, {Arianne L.} and Edaire Cheng and Qiuyang Zhang and Alexander Zaika and Pham, {Thai H.} and Wang, {David H.} and Lobie, {Peter E.} and Odze, {Robert D.} and Spechler, {Stuart J.} and Souza, {Rhonda F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1152/ajpgi.00462.2014",
language = "English (US)",
volume = "309",
pages = "G146--G161",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Mitochondrial STAT3 contributes to transformation of barrett’s epithelial cells that express oncogenic ras in a p53-independent fashion

AU - Yu, Chunhua

AU - Huo, Xiaofang

AU - Agoston, Agoston T.

AU - Zhang, Xi

AU - Theiss, Arianne L.

AU - Cheng, Edaire

AU - Zhang, Qiuyang

AU - Zaika, Alexander

AU - Pham, Thai H.

AU - Wang, David H.

AU - Lobie, Peter E.

AU - Odze, Robert D.

AU - Spechler, Stuart J.

AU - Souza, Rhonda F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Metaplastic epithelial cells of Barrett’s esophagus transformed by the combination of p53-knockdown and oncogenic Ras expression are known to activate signal transducer and activator of transcription 3 (STAT3). When phosphorylated at tyrosine 705 (Tyr705), STAT3 functions as a nuclear transcription factor that can contribute to oncogenesis. STAT3 phosphorylated at serine 727 (Ser727) localizes in mitochondria, but little is known about mitochondrial STAT3’s contribution to carcinogenesis in Barrett’s esophagus, which is the focus of this study. We introduced a constitutively active variant of human STAT3 (STAT3CA) into the following: 1) non-neoplastic Barrett’s (BAR-T) cells; 2) BAR-T cells with p53 knockdown; and 3) BAR-T cells that express oncogenic H-RasG12V. STAT3CA transformed only the H-RasG12V-expressing BAR-T cells (evidenced by loss of contact inhibition, formation of colonies in soft agar, and generation of tumors in immunodeficient mice), and did so in a p53-independent fashion. The transformed cells had elevated levels of both mitochondrial (Ser727) and nuclear (Tyr705) phospho-STAT3. Introduction of a STAT3CA construct with a mutated tyrosine phosphorylation site into H-RasG12V-expressing Barrett’s cells resulted in high levels of mitochondrial phospho-STAT3 (Ser727) with little or no nuclear phospho-STAT3 (Tyr705), and the cells still formed tumors in immunodeficient mice. Thus tyrosine phosphorylation of STAT3 is not required for tumor formation in Ras-expressing Barrett’s cells. We conclude that mitochondrial STAT3 (Ser727) can contribute to oncogenesis in Barrett’s cells that express oncogenic Ras. These findings suggest that agents targeting STAT3 might be useful for chemoprevention in patients with Barrett’s esophagus.

AB - Metaplastic epithelial cells of Barrett’s esophagus transformed by the combination of p53-knockdown and oncogenic Ras expression are known to activate signal transducer and activator of transcription 3 (STAT3). When phosphorylated at tyrosine 705 (Tyr705), STAT3 functions as a nuclear transcription factor that can contribute to oncogenesis. STAT3 phosphorylated at serine 727 (Ser727) localizes in mitochondria, but little is known about mitochondrial STAT3’s contribution to carcinogenesis in Barrett’s esophagus, which is the focus of this study. We introduced a constitutively active variant of human STAT3 (STAT3CA) into the following: 1) non-neoplastic Barrett’s (BAR-T) cells; 2) BAR-T cells with p53 knockdown; and 3) BAR-T cells that express oncogenic H-RasG12V. STAT3CA transformed only the H-RasG12V-expressing BAR-T cells (evidenced by loss of contact inhibition, formation of colonies in soft agar, and generation of tumors in immunodeficient mice), and did so in a p53-independent fashion. The transformed cells had elevated levels of both mitochondrial (Ser727) and nuclear (Tyr705) phospho-STAT3. Introduction of a STAT3CA construct with a mutated tyrosine phosphorylation site into H-RasG12V-expressing Barrett’s cells resulted in high levels of mitochondrial phospho-STAT3 (Ser727) with little or no nuclear phospho-STAT3 (Tyr705), and the cells still formed tumors in immunodeficient mice. Thus tyrosine phosphorylation of STAT3 is not required for tumor formation in Ras-expressing Barrett’s cells. We conclude that mitochondrial STAT3 (Ser727) can contribute to oncogenesis in Barrett’s cells that express oncogenic Ras. These findings suggest that agents targeting STAT3 might be useful for chemoprevention in patients with Barrett’s esophagus.

KW - Esophagus

KW - Human

KW - Nuclear

KW - Tumorigenesis

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=84938598880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938598880&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00462.2014

DO - 10.1152/ajpgi.00462.2014

M3 - Article

VL - 309

SP - G146-G161

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 3

ER -